Structure-based development of Antagonists for Chemokine receptor CXCR4

Current Computer-Aided Drug Design

Volumn 9, Issue 1, 2013, Pages 60-75

  Zhang, Chongqian ^a   Hou, Tingjun ^a   Feng, Zhiwei ^a   Li, Youyong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Anti HIV 1 inhibitors; Critical residues; Crystal structure; CXCR4; DOCK; Drug development; Molecular dynamics; SAR

Indexed keywords

CRYSTAL STRUCTURE; CYTOLOGY; DISEASES; MAMMALS; PATHOLOGY;

ACTIVE COMPOUNDS; ANTI-HIV; ANTI-HIV-1 INHIBITOR; C-X-C CHEMOKINE RECEPTOR-4; CHEMOKINE RECEPTORS; CRITICAL RESIDUE; CRYSTALS STRUCTURES; DRUG DEVELOPMENT; G PROTEIN COUPLED RECEPTORS; STRUCTURE-BASED;

MOLECULAR DYNAMICS;

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; RHODOPSIN;

ARTICLE; CALCIUM SIGNALING; CELL MEDIATED CYTOTOXICITY; CELL MEMBRANE; CRYSTAL STRUCTURE; DRUG DESIGN; HUMAN; INFLAMMATION; LIGAND BINDING; METASTASIS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; STRUCTURE ACTIVITY RELATION;

EID: 84876868095     PISSN: 15734099     EISSN: 18756697     Source Type: Journal    
DOI: 10.2174/157340913804998739     Document Type: Article

References (125)

1. Dolin, R. HIV vaccine trial results -an opening for further research. N. Engl. J. Med., 2009, 361, 2279-2280.
2. Lin, P.F.; Blair, W.; Wang, T.; Spicer, T.; Guo, Q.; Zhou, N.N.; Gong, Y.F.; Wang, H.G.H.; Rose, R.; Yamanaka, G.; Robinson, B.; Li, C.B.; Fridell, R.; Deminie, C.; Demers, G.; Yang, Z.; Zadjura, L.; Meanwell, N.; Colonno, R. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding Proc. Natl. Acad. Sci. USA, 2003, 100, 11013-11018.
3. Li, Y.X.; Migueles, S.A.; Welcher, B.; Svehla, K.; Phogat, A.; Louder, M.K.; Wu, X.L.; Shaw, G.M.; Connors, M.; Wyatt, R.T.; Mascola, J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med., 2007, 13, 1032-1034.
4. Kilby, J.M.; Eron, J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med., 2003, 348, 2228-2238.
5. Ho, H.T.; Fan, L.; Nowicka-Sans, B.; McAuliffe, B.; Li, C.B.; Yamanaka, G.; Zhou, N.N.; Fang, H.; Dicker, I.; Dalterio, R.; Gong, Y.F.; Wang, T.; Yin, Z.W.; Ueda, Y.; Matiskella, J.; Kadow, J.; Clapham, P.; Robinson, J.; Colonno, R.; Lin, P.F. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol., 2006, 80, 4017-4025.
6. Guo, Q.; Ho, H.T.; Dicker, I.; Fan, L.; Zhou, N.N.; Friborg, J.; Wang, T.; McAuliffe, B.V.; Wang, H.G.H.; Rose, R.E.; Fang, H.; Scarnati, H.T.; Langley, D.R.; Meanwell, N.A.; Abraham, R.; Colonno, R.J.; Lin, P.F. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol., 2003, 77, 10528-10536.
7. Poveda, E.; Briz, V.; Soriano, V. Enfuvirtide, the first fusion inhibitor to treatHIV infection. Aids Rev., 2005, 7, 139-147.
8. Brelot, A.; Heveker, N.; Montes, M.; Alizon, M. Identification of residues of CXCR4 critical for human immunodeficiency virus co-receptor and chemokine receptor activities. J. Biol. Chem., 2000, 275, 23736-23744.
9. Briz, V.; Poveda, E.; Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chem., 2006, 57, 619-627.
10. Cane, P.A. New developments in HIV drug resistance. J. Antimicrob. Chemother., 2009, 64, 37-40.
11. Cheung, P.K.; Wynhoven, B.; Harrigan, R.R. 2004: Which HIV-1 drug resistance mutations are common in clinical practice? AIDS. Rev., 2004, 6, 107-116.
12. Streeck, H.; Jessen, H.; Alter, G.; Teigen, N.; Waring, M.T.; Jessen, A.; Stahmer, I.; van Lunzen, J.; Lichterfeld, M.; Gao, X.J.; Allen, T.M.; Carrington, M.; Walker, B.D.; Rockstroh, J.K.; Altfeld, M. Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J. Infect. Dis., 2006, 194, 734-739.
13. Desquilbet, L.; Goujard, C.; Rouzioux, C.; Sinet, M.; Deveau, C.; Chaix, M.L.; Sereni, D.; Boufassa, F.; Delfraissy, J.F.; Meyer, L.; Grp, P.a.S.S. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS, 2004, 18, 2361-2369.
14. Rotheram-Borus, M.J.; Swendeman, D.; Chovnick, G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu. Rev. Clin. Psychol., 2009, 5, 143-167.
15. VantWout, A.B.; Ran, L.J.; Kuiken, C.L.; Kootstra, N.A.; Pals, S.T.; Schuitemaker, H. Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J. Virol., 1998, 72, 488-496.
16. Chan, S.Y.; Speck, R.F.; Power, C.; Gaffen, S.L.; Chesebro, B.; Goldsmith, M.A. V3 recombinants indicate a central role for CCR5 as a coreceptor in tissue infection by human immunodeficiency virus type 1. J. Virol., 1999, 73, 2350-2358.
17. Wensing, A.M.J.; van de Vijver, D.A.; Angarano, G. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis., 2005, 192, 1501-1501.
18. Hendrix, C.W.; Flexner, C.; MacFarland, R.T.; Giandomenico, C.; Fuchs, E.J.; Redpath, E.; Bridger, G.; Henson, G.W. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob. Agents. Chemother., 2000, 44, 1667-1673.
19. Carr, A. Enfuvirtide, an HIV-1 fusion inhibitor. N. Engl. J. Med., 2003, 349, 1770-1770.
20. Mosley, C.A.; Wilson, L.J.; Wiseman, J.M.; Skudlarek, J.W.; Liotta, D.C. Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin. Ther. Pat., 2009, 19, 23-38.
21. Tamamura, H.; Araki, T.; Ueda, S.; Wang, Z.X.; Oishi, S.; Esaka, A.; Trent, J.O.; Nakashima, H.; Yamamoto, N.; Peiper, S.C.; Otaka, A.; Fujii, N. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds. J. Med. Chem., 2005, 48, 3280-3289.
22. Tamamura, H.; Omagari, A.; Hiramatsu, K.; Gotoh, K.; Kanamoto, T.; Xu, Y.N.; Kodama, E.; Matsuoka, M.; Hattori, T.; Yamamoto, N.; Nakashima, H.; Otaka, A.; Fujii, N. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg. Med. Chem. Lett., 2001, 11, 1897-1902.
23. Cluzeau, J.; Oishi, S.; Ohno, H.; Wang, Z.; Evans, B.; Peiper, S.C.; Fujii, N. Design and synthesis of all diastereomers of cyclic pseudo-dipeptides as mimics of cyclic CXCR4 pentapeptide antagonists. Org. Biomol. Chem., 2007, 5, 1915-1923.
24. Hatse, S.; Princen, K.; De Clercq, E.; Rosenkilde, M.M.; Schwartz, T.W.; Hernandez-Abad, P.E.; Skerlj, R.T.; Bridger, G.J.; Schols, D. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem. Pharmacol., 2005, 70, 752-761.
25. Este, J.A.; Cabrera, C.; De Clercq, E.; Struyf, S.; Van Damme, J.; Bridger, G.; Skerlj, R.T.; Abrams, M.J.; Henson, G.; Gutierrez, A.; Clotet, B.; Schols, D. Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor. Mol. Pharmacol., 1999, 55, 67-73.
26. De Clercq, E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol. Pharmacol., 2000, 57, 833-839.
27. Bridger, G.J.; Skerlj, R.T.; Padmanabhan, S.; Martellucci, S.A.; Henson, G.W.; Struyf, S.; Witvrouw, M.; Schols, D.; De Clercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-8 replication by antagonism of the chemokine receptor CXCR4. J. Med. Chem., 1999, 42, 3971-3981.
28. Egberink, H.F.; De Clercq, E.; Van Vliet, A.L.W.; Balzarini, J.; Bridger, G.J.; Henson, G.; Horzinek, M.C.; Schols, D. Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication. J. Virol., 1999, 73, 6346-6352.
29. Princen, K.; Hatse, S.; Vermeire, K.; Aquaro, S.; De Clercq, E.; Gerlach, L.O.; Rosenkilde, M.; Schwartz, T.W.; Skerlj, R.; Bridger, G.; Schols, D. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist. J. Virol., 2004, 78, 12996-13006.
30. Ichiyama, K.; Yokoyama-Kumakura, S.; Tanaka, Y.; Tanaka, R.; Hirose, K.; Bannai, K.; Edamatsu, T.; Yanaka, M.; Niitani, Y.; Miyano-Kurosaki, N.; Takaku, H.; Koyanagi, Y.; Yamamoto, N. A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 2003, 100, 4185-4190.
31. Yamazaki, T.; Kikumoto, S.; Ono, M.; Saitou, A.; Takahashi, H.; Kumakura, S.; Hirose, K.; Yanaka, M.; Takemura, Y.; Suzuki, S. Amine compounds and use thereof. Japanese 4,064,697, September 05, 2004.
32. Yamazaki, T.; Saitou, A.; Ono, M.; Yokoyama, S.; Bannai, K.; Hirose, K.; Yanaka, M. Japanese.3/029,218, September 27, 2003.
33. Murakami, T.; Kumakura, S.; Yamazaki, T.; Tanaka, R.; Hamatake, M.; Okuma, K.; Huang, W.; Toma, J.; Komano, J.; Yanaka, M.; Tanaka, Y.; Yamamoto, N. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob. Agents Chemother., 2009, 53, 2940-2948.
34. Jenkinson, S.; Thomson, M.; McCoy, D.; Edelstein, M.; Danehower, S.; Lawrence, W.; Wheelan, P.; Spaltenstein, A.; Gudmundsson, K. Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent non-competitive CXCR4 receptor antagonist. Antimicrob. Agents Chemother., 2010, 54, 817-824.
35. Catalano, J.G.; Gudmundsson, K.S.; Svolto, A.; Boggs, S.D.; Miller, J.F.; Spaltenstein, A.; Thomson, M.; Wheelan, P.; Minick, D.J.; Phelps, D.P.; Jenkinson, S. Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1. Bioorg. Med. Chem. Lett., 2010, 20, 2186-2190.
36. Bridger, G.J.; Skerlj, R.T.; Hernandez-Abad, P.E.; Bogucki, D.E.; Wang, Z.R.; Zhou, Y.X.; Nan, S.; Boehringer, E.M.; Wilson, T.; Crawford, J.; Metz, M.; Hatse, S.; Princen, K.; De Clercq, E.; Schols, D. Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication. J. Med. Chem., 2010, 53, 1250-1260.
37. Moyle, G.; DeJesus, E.; Boffito, M.; Wong, R.S.; Gibney, C.; Badel, K.; MacFarland, R.; Calandra, G.; Bridger, G.; Becker, S.; Study, X.A.C.T. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin. Infect. Dis., 2009, 48, 798-805.
38. Pettersson, S.; Perez-Nueno, V.I.; Mena, M.P.; Clotet, B.; Este, J.A.; Borrell, J.I.; Teixido, J. Novel monocyclam derivatives as HIV entry inhibitors: design, synthesis, anti-HIV evaluation, and their interaction with the CXCR4 co-receptor. ChemMedChem., 2010, 5, 1272-1281.
39. Boulais, P.E.; Dulude, D.; Cabana, J.; Heveker, N.; Escher, E.; Lavigne, P.; Leduc, R. Photolabeling identifies transmembrane domain 4 of CXCR4 as a T140 binding site. Biochem. Pharmacol., 2009, 78, 1382-1390.
40. Kawatkar, S.P.; Yan, M.C.; Gevariya, H.; Lim, M.Y.; Eisold, S.; Zhu, X.J.; Huang, Z.W.; An, J. Computational analysis of the structural mechanism of inhibition of chemokine receptor CXCR4 by small molecule antagonists. Exp. Biol. Med., 2011, 236, 844-850.
41. Veldkamp, C.T.; Seibert, C.; Peterson, F.C.; De la Cruz, N.B.; Haugner, J.C.; Basnet, H.; Sakmar, T.P.; Volkman, B.F. Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-1/CXCL12. Sci. Signal., 2008, 1, ra4.
42. Kim, S.-K.; Li, Y.; Abrol, R.; Heo, J.; Goddard, W.A. III. Predicted structures and dynamics for agonists and antagonists bound toserotonin 5-HT2B and 5-HT2C receptors. J. Chem. Inf. Model., 2011, 51, 420-433.
43. Kim, S.-K.; Li, Y.; Park, C.; Abrol, R.; Goddard, W.A., III. Prediction of the three-dimensional structure for the rat urotensin II receptor, and comparison of the antagonist binding sites and binding selectivity between human and rat receptors from atomistic simulations. ChemMedChem., 2010, 5, 1594-1608.
44. Kalani, M.Y.S.; Vaidehi, N.; Hall, S.E.; Trabanino, R.J.; Freddolino, P.L.; Kalani, M.A.; Floriano, W.B.; Kam, V.W.T.; Goddard, W.A. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. USA, 2004,101, 3815-3820.
45. Li, Y.; Hou, T. Computational simulation of drug delivery at molecular level. Curr. Med. Chem., 2010, 17, 4482-4491.
46. Li, Y.; Zhu, F.; Vaidehi, N.; Goddard, W.A., III; Sheinerman, F.; Reiling, S.; Morize, I.; Mu, L.; Harris, K.; Ardati, A.; Laoui, A. Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist. J. Am. Chem. Soc., 2007, 129, 10720-10731.
47. Li, Y.Y.; Hou, T.J.; Goddard, W.A., III. Computational modeling of structure-function of G protein-coupled receptors with applications for drug design. Curr. Med. Chem., 2010, 17, 1167-1180.
48. Harrison, C. G protein-coupled receptors: Insights into chemokine receptors. Nat. Rev. Drug. Discov., 2010, 9, 920-920.
49. Wu, B.L.; Chien, E.Y.T.; Mol, C.D.; Fenalti, G.; Liu, W.; Katritch, V.; Abagyan, R.; Brooun, A.; Wells, P.; Bi, F.C.; Hamel, D.J.; Kuhn, P.; Handel, T.M.; Cherezov, V.; Stevens, R.C. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science, 2010, 330, 1066-1071.
50. Murakami, T.; Yamamoto, N. Role of CXCR4 in HIV infection and its potential as a therapeutic target. Future Microbiol., 2010, 5, 1446-1446.
51. Babcock, G.J.; Farzan, M.; Sodroski, J. Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor. J. Biol. Chem. 2003, 278, 3378-3385.
52. Percherancier, Y.; Berchiche, Y.A.; Slight, I.; Volkmer-Engert, R.; Tamamura, H.; Fujii, N.; Bouvier, M.; Heveker, N. Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo-and heterodimers. J. Biol. Chem., 2005, 280, 9895-9903.
53. De Clercq, E. New developments in anti-HIV chemotherapy. Farmaco, 2001, 56, 3-12.
54. Sohy, D.; Parmentier, M.; Springael, J.Y. Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J. Biol. Chem., 2007, 282, 30062-30069.
55. De Clercq, E.; Yamamoto, N.; Pauwels, R.; Balzarini, J.; Witvrouw, M.; De Vreese, K.; Debyser, Z.; Rosenwirth, B.; Peichl, P.; Datema, R. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother., 1994, 38, 668-674.
56. De Vreese, K.; Reymen, D.; Griffin, P.; Steinkasserer, A.; Werner, G.; Bridger, G.J.; James, W.; Henson, G.W.; Desmyter, J. The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Res., 1996, 29, 209-219.
57. Feng, Y.; Broder, C.C.; Kennedy, P.E.; Berger, E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science, 1996, 272, 872-877.
58. Donzella, G.A.; Schols, D.; Lin, S.W.; Nagashima, K.A.; Maddon, P.J.; Allaway, G.P.; Sakmar, T.P.; Henson, G.; DeClercq, E. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med., 1998, 4, 72-77.
59. Schols, D.; Struyf, S.; Damme, J.V.; Henson, G.; Clercq, E.D. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med., 1997, 186, 1383-1388.
60. Bleul, C.C.; Farzan, M.; Choe, H.; Parolin, C.; Clark-Lewis, I.; Sodroski, J.; Springer, T.A. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature, 1996, 382, 829-833.
61. Hatse, S.; Princen, K.; Bridger, G.; De Clercq, E.; Schols, D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett., 2002, 527, 255-262.
62. Oberlin, E.; Ali Amara, F. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 1996, 382, 833-835.
63. Pettersson, S.; Perez-Nueno, V.I.; Ros-Blanco, L.; de La Bellacasa, R.P.; Rabal, M.O.; Batllori, X.; Clotet, B.; Clotet-Codina, I.; Armand-Ugon, M.; Este, J.; Borrell, J.I.; Teixido, J. Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors. ChemMedChem, 2008, 3, 1549-1557.
64. Flomenberg, N.; Devine, S.M.; DiPersio, J.F.; Liesveld, J.L.; McCarty, J.M.; Rowley, S.D.; Vesole, D.H.; Badel, K.; Calandra, G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood, 2005, 106, 1867-1874.
65. Gerlach, L.O.; Skerlj, R.T.; Bridger, G.J.; Schwartz, T.W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem., 2001, 276, 14153-14160.
66. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745.
67. Hatse, S.; Princen, K.; Gerlach, L.O.; Bridger, G.; Henson, G.; De Clercq, E.; Schwartz, T. W.; Schols, D. Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol. Pharm., 2001, 60, 164-173.
68. Wong, R.S.Y.; Bodart, V.; Metz, M.; Labrecque, J.; Bridger, G.; Fricker, S.P. Comparison of the potential multiple binding modes of bicyclam, monocylam, and non-cyclam small-molecule CXC chemokine receptor 4 inhibitors. Mol. Pharmacol., 2008, 74, 1485-1495.
69. Tian, S.M.; Choi, W.T.; Liu, D.X.; Pesavento, J.; Wang, Y.L.; An, J.; Sodroski, J.G.; Huang, Z.W. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1 alpha on CXCR4 transmembrane helical domains. J. Virol., 2005, 79, 12667-12673.
70. Rosenkilde, M.M.; Gerlach, L.O.; Hatse, S.; Skerlj, R.T.; Schols, D.; Bridger, G.J.; Schwartz, T.W. Molecular mechanism of action of Monocyclam vs Bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J. Biol. Chem., 2007, 282, 27354-27365.
71. Bridger, G.J.; Skerlj, R.T.; Padmanabhan, S.; Martellucci, S.A.; Henson, G.W.; Abrams, M.J.; Joao, H.C.; Witvrouw, M.; DeVreese, K.; Pauwels, R.; DeClercq, E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit human immunodeficiency virus replication. Effect of heteroaromatic linkers on the activity of bicyclams. J. Med. Chem., 1996, 39, 109-119.
72. Bridger, G.J.; Skerlj, R.T.; Thornton, D.; Padmanabhan, S.; Martellucci, S.A.; Henson, G.W.; Abrams, M.J.; Yamamoto, N.; Devreese, K.; Pauwels, R.; Declercq, E. Synthesis and structure-activity-relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication -effects of macrocyclic ring size and substituents on the aromatic linker. J. Med. Chem., 1995, 38, 366-378.
73. Joao, H.C.; De Vreese, K.; Pauwels, R.; De Clercq, E.; Henson, G.W.; Bridger, G.J. Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors. J. Med. Chem., 1995, 38, 3865-3873.
74. Sohy, D.; Yano, H.; de Nadai, P.; Urizar, E.; Guillabert, A.; Javitch, J.A.; Parmentier, M.; Springael, J.Y. Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J. Biol. Chem., 2009, 284, 31270-31279.
75. Baribaud, F.; Edwards, T.G.; Sharron, M.; Brelot, T.; Heveker, N.; Price, K.; Mortari, F.; Alizon, M.; Tsang, M.; Doms, R.W. Antigenically distinct conformations of CXCR4. J. Virol., 2001, 75, 8957-8967.
76. Kazmierski, W.M.; Gudmundsson, K.S.; Piscitelli, S.C. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-hiv therapy currently in development. Annu. Rep. Med. Chem., 2007, 42, 301-320.
77. Stone, N.D.; Dunaway, S.B.; Flexner, C.; Tierney, C.; Calandra, G.B.; Becker, S.; Cao, Y.J.; Wiggins, I.P.; Conley, J.; MacFarland, R.T.; Park, J.G.; Lalama, C.; Snyder, S.; Kallungal, B.; Klingman, K.L.; Hendrix, C.W. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob. Agents Chemother., 2007, 51, 2351-2358.
78. Rosenkilde, M.M.; Gerlach, L.O.; Hatse, S.; Skerlj, R.T.; Schols, D.; Bridger, G.J.; Schwartz, T.W. Molecular mechanism of action of Monocyclam vs Bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J. Biol. Chem., 2007, 282, 27354-27365.
79. Grande, F.; Garofalo, A.; Neamati, N. Small molecules anti-HIV therapeutics targeting CXCR4. Curr. Pharm. Des., 2008, 14, 385-404.
80. Neves, M.A.C.; Simoes, S.; Melo, M.L.S.E. Ligand-guided optimization of CXCR4 homology models for virtual screening using a multiple chemotype approach. J. Comput. Aid. Mol. Des., 2010, 24, 1023-1033.
81. Crawford, J.B.; Chen, G.; Gauthier, D.; Wilson, T.; Carpenter, B.; Baird, L.R.; McEachern, E.; Kaller, A.; Harwig, C.; Atsma, B.; Skerlj, R.T.; Bridger, G.J. AMD070, a CXCR4 chemokine receptor antagonist: Practical large-scale laboratory synthesis. Org. Process. Res. Dev., 2008, 12, 823-830.
82. Stone, N.D.; Dunaway, S.B.; Flexner, C.; Tierney, C.; Calandra, G.B.; Becker, S.; Cao, Y.-J.; Wiggins, I.P.; Conley, J.; MacFarland, R.T.; Park, J.-G.; Lalama, C.; Snyder, S.; Kallungal, B.; Klingman, K.L.; Hendrix, C.W. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob. Agents Chemother., 2007, 51, 3047-3047.
83. Este, J.A.; Cabrera, C.; Blanco, J.; Gutierrez, A.; Bridger, G.; Henson, G.; Clotet, B.; Schols, D.; De Clercq, E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J.Virol., 1999, 73, 5577-5585.
84. Vabeno, J.; Nikiforovich, G.V.; Marshall, G.R. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists. Biopolymers, 2006, 84, 459-471.
85. Iwasaki, Y.; Akari, H.; Murakami, T.; Kumakura, S.; Dewan, M.Z.; Yanaka, M.; Yamamoto, N. Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci., 2009, 100, 778-781.
86. Briz, V.; Poveda, E.; Soriano, V. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother., 2006, 57, 619-627.
87. Murakami, T.; Yoshida, A.; Tanaka, R.; Mitsuhashi, S.; Hirose, K.; Yanaka, M.; Yamamoto, N.; Tanaka, Y. KRH-2731: an orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection. J. Immunol. Methods, 1991, 142, 527-265.
88. De Clercq, E. The AMD3100 story: The path to the discovery of a stem cell. Biochem. Pharmacol., 2009, 7, 1655-1664.
89. Ketas, T.J.; Schader, S.M.; Zurita, J.; Teo, E.; Polonis, V.; Lu, M.; Klasse, P.J.; Moore, J.P. Entry inhibitor-based microbicides are active in vitro against HTV-1 isolates from multiple genetic subtypes. Virology, 2007, 364, 431-440.
90. Hendrix, C.W.; Collier, A.C.; Lederman, M.M.; Schols, D.; Pollard, R.B.; Brown, S.; Jackson, J.B.; Coombs, R.W.; Gleshy, M.J.; Flexner, C.W.; Bridger, G.J.; Badel, K.; MacFarland, R.T.; Henson, G.W.; Calandra, G.; Grp, A.H.S. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr., 2004, 37, 1253-1262.
91. Skerlj, R.T.; Bridger, G.J.; Caller, A.; McEachern, E.J.; Crawford, J.B.; Zhou, Y.X.; Atsma, B.; Langille, J.; Nan, S.; Veale, D.; Wilson, T.; Harwig, C.; Hatse, S.; Princen, K.; De Clercq, E.; Schols, D. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J. Med. Chem., 2010, 53, 3376-3388.
92. Wilkinson, R.A.; Pincus, S.H.; Shepard, J.B.; Walton, S.K.; Bergin, E.P.; Labib, M.; Teintze, M. Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4. Antimicrob. Agents Chemother., 2011, 55, 255-263.
93. Zhan, W.Q.; Liang, Z.X.; Zhu, A.Z.; Kurtkaya, S.; Shim, H.; Snyder, J.P.; Liotta, D.C. Discovery of small molecule CXCR4 antagonists. J. Med. Chem., 2007, 50, 5655-5664.
94. Gudmundsson, K.S.; Sebahar, P.R.; Richardson, L.D.; Miller, J.F.; Turner, E.M.; Catalano, J.G.; Spaltenstein, A.; Lawrence, W.; Thomson, M.; Jenkinson, S. Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1. Bioorg. Med. Chem. Lett., 2009, 19, 5048-5052.
95. Miller, J.F.; Gudmundsson, K.S.; Richardson, L.D.; Jenkinson, S.; Spaltenstein, A.; Thomson, M.; Wheelan, P. Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity. Bioorg. Med. Chem. Lett., 2010, 20, 3026-3030.
96. Skerlj, R.; Bridger, G.; McEachern, E.; Harwig, C.; Smith, C.; Wilson, T.; Veale, D.; Yee, H.; Crawford, J.; Skupinska, K.; Wauthy, R.; Yang, W.; Zhu, Y.B.; Bogucki, D.; Di Fluri, M.; Langille, J.; Huskens, D.; De Clercq, E.; Schols, D. Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication. Bioorg. Med. Chem. Lett., 2011, 21, 262-266.
97. Thoma, G.; Streiff, M.B.; Kovarik, J.; Glickman, F.; Wagner, T.; Beerli, C.; Zerwes, H.G. Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J. Med. Chem., 2008, 51, 7915-7920.
98. Gouwy, M.; Struyf, S.; Berghmans, N.; Vanormelingen, C.; Schols, D.; Van Damme, J. CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection. Eur. J. Immunol., 2011, 41, 963-973.
99. Benamar, K.; Yondorf, M.; Geller, E.B.; Eisenstein, T.K.; Adler, M.W. Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. Br. J. Pharmacol., 2009, 157, 1225-1231.
100. Tamamura, H.; Tsutsumi, H.; Masuno, H.; Fujii, N. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra-and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Curr. Med. Chem., 2007, 14, 93-102.
101. Kazmierski, W.M.; Gudmundsson, K.S.; Piscitelli, S.C. Small molecule CCR5 and CXCR4-based viral entry inhibitors for anti-HIV therapy currently in development. Annu. Rep. Med. Chem., 2007, 42, 301-320.
102. Singh, I.P.; Chauthe, S.K. Small molecule HIV entry inhibitors: Part I. Chemokine receptor antagonists: 2004-2010. Expert Opin. Ther. Pat., 2011, 21, 227-269.
103. Madani, N.; Perdigoto, A.L.; Srinivasan, K.; Cox, J.M.; Chruma, J.J.; LaLonde, J.; Head, M.; Smith, A.B.; Sodroski, J.G. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors. J. Virol., 2004, 78, 3742-3752.
104. Shet, A.; Berry, L.; Mohri, H.; Mehandru, S.; Chung, C.; Kim, A.; Jean-Pierre, P.; Hogan, C.; Simon, V.; Boden, D.; Markowitz, M.T. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1 -A decade of experience. J. Acquir. Immune Defic. Syndr., 2006, 41, 439-446.
105. Bannister, W.P.; Cozzi-Lepri, A.; Clotet, B.; Mocroft, A.; Kjaer, J.; Reiss, P.; von Wyl, V.; Lazzarin, A.; Katlama, C.; Phillips, A.N.; Ruiz, L.; Lundgren, J.D.; Grp, E.S. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination Antiretroviral therapy in the EuroSIDA study. J. Acquir. Immune Defic. Syndr., 2008, 48, 324-333.
106. Gianella, S.; Richman, D.D. Minority variants of drug-resistant HIV. J. Infect. Dis., 2010, 202, 657-666.
107. Cooper, D.A.; Steigbigel, R.T.; Gatell, J.M.; Rockstroh, J.K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P.N.; Eron, J.E.; Schechter, M.; Markowitz, M.; Loutfy, M.R.; Lennox, J.L.; Zhao, J.; Chen, J.; Ryan, D.M.; Rhodes, R.R.; Killar, J.A.; Gilde, L.R.; Strohmaier, K.M.; Meibohm, A.R.; Miller, M.D.; Hazuda, D.J.; Nessly, M.L.; DiNubile, M.J.; Isaacs, R.D.; Teppler, H.; Nguyen, B.Y.; Teams, B.S. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med., 2008, 359, 355-365.
108. Rubin, J.B.; Kung, A.L.; Klein, R.S.; Chan, J.A.; Sun, Y.P.; Schmidt, K.; Kieran, M.W.; Luster, A.D.; Segal, R.A. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl. Acad. Sci. USA, 2003, 100, 13513-13518.
109. Seibert, C.; Sakmar, T.P. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr. Pharm. Des., 2004, 10, 2041-2062.
110. Liang, X.Y. CXCR4, inhibitors and mechanisms of action. Chem. Biol. Drug Des., 2008, 72, 97-110.
111. Perez-Nueno, V.I.; Pettersson, S.; Ritchie, D.W.; Borrell, J.I.; Teixido, J. Discovery of novel HIV entry inhibitors for the CXCR4 receptor by prospective virtual screening. J. Chem. Inf. Model., 2009, 49, 810-823.
112. Zhan, W.Q.; Liang, Z.X.; Zhu, A.Z.; Kurtkaya, S.; Shim, H.; Snyder, J.P.; Liotta, D.C. Discovery of small molecule CXCR4 antagonists. J. Med. Chem., 2007, 50, 5655-5664.
113. Khan, A.; Greenman, J.; Archibald, S.J. Small molecule CXCR4 chemokine candidates receptor antagonists: developing drug candidates. Curr. Med. Chem., 2007, 14, 2257-2277.
114. Proudfoot, A.E.I.; Power, C.A.; Schwarz, M.K. Anti-chemokine small molecule drugs: a promising future? Expert Opin. Inv. Drug., 2010, 19, 345-355.
115. Wei, X.P.; Decker, J.M.; Liu, H.M.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.Y.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother., 2002, 46, 1896-1905.
116. Sista, P.R.; Melby, T.; Davison, D.; Jin, L.; Mosier, S.; Mink, M.; Nelson, E.L.; DeMasi, R.; Cammack, N.; Salgo, M.P.; Matthews, T.J.; Greenberg, M.L. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS, 2004, 18, 1787-1794.
117. Poveda, E.; Rodes, B.; Labernardiere, J.L.; Benito, J.M.; Toro, C.; Gonzalez-Lahoz, J.; Faudon, J.L.; Clavel, F.; Schapiro, J.; Soriano, V. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J. Med. Virol., 2004, 74, 21-28.
118. Poveda, E.; Rodes, B.; Lebel-Binay, S.; Faudon, J.L.; Jimenez, V.; Soriano, V. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J. Clin. Virol., 2005, 34, 295-301.
119. Lohrengel, S.; Hermann, F.; Hagmann, I.; Oberwinkler, H.; Scrivano, L.; Hoffmann, C.; von Laer, D.; Dittmar, M.T. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J. Virol., 2005, 79, 10237-10246.
120. Eckert, D.M.; Malashkevich, V.N.; Hong, L.H.; Carr, P.A.; Kim, P.S. Inhibiting HIV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell, 1999, 99, 103-115.
121. Hartley, O.; Gaertner, H.; Wilken, J.; Thompson, D.; Fish, R.; Ramos, A.; Pastore, C.; Dufour, B.; Cerini, F.; Melotti, A.; Heveker, N.; Picard, L.; Alizon, M.; Mosier, D.; Kent, S.; Offord, R. Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. USA, 2004, 101, 16460-16465.
122. Moore, J.P.; Stevenson, M. New targets for inhibitors of HIV-1 replication. Nat. Rev. Mol. Cell. Biol., 2000, 1, 40-49.
123. De Clercq, E. New developments in anti-HIV chemotherapy. Curr. Med. Chem., 2001, 8, 1543-1572.
124. De Clercq, E. New developments in anti-HIV chemotherapy. Pure Appl. Chem., 2001, 73, 55-66.
125. Pinheiro, E.; Vasan, A.; Kim, J.Y.; Lee, E.; Guimier, J.M.; Perriens, J. Examining the production costs of antiretroviral drugs. AIDS, 2006, 20, 1745-1752.